Literature DB >> 16644752

Estimation of serotonin transporter parameters with 11C-DASB in healthy humans: reproducibility and comparison of methods.

W Gordon Frankle1, Mark Slifstein, Roger N Gunn, Yiyun Huang, Dah-Ren Hwang, E Ashlie Darr, Rajesh Narendran, Anissa Abi-Dargham, Marc Laruelle.   

Abstract

UNLABELLED: The aim of the present study was to define the optimal analytic method to derive accurate and reliable serotonin transporter (SERT) receptor parameters with (11)C-3-amino-4-(2-[(dimethylamino)methyl]phenylthio)benzonitrile ((11)C-DASB).
METHODS: Nine healthy subjects (5 females, 4 males) underwent two (11)C-DASB PET scans on the same day. Five analytic methods were used to estimate binding parameters in 10 brain regions: compartmental modeling with 1- and 2-tissue compartment models (1TC and 2TC), data-driven estimation of parametric images based on compartmental theory (DEPICT) analysis, graphical analysis, and the simplified reference tissue model (SRTM). Two variations in the fitting procedure of the SRTM method were evaluated: nonlinear optimization and basis function approach. The test/retest variability (VAR) and intraclass correlation coefficient (ICC or reliability) were assessed for 3 outcome measures: distribution volume (V(T)), binding potential (BP), and specific to nonspecific equilibrium partition coefficient (V(3)'').
RESULTS: All methods gave similar values across all regions. The variability of V(T) was excellent (< or =10%) in all regions, for the 1TC, 2TC, DEPICT, and graphical approaches. The variability of BP and V(3)'' was good in regions of high SERT density and poorer in regions of moderate and lower densities. The ICC of all 3 outcome measures was excellent in all regions. The basis function implementation of SRTM demonstrated improved reliability compared with nonlinear optimization, particularly in moderate and low-binding regions.
CONCLUSION: The results of this study indicate that (11)C-DASB can be used to measure SERT parameters with high reliability and low variability in receptor-rich regions of the brain, with somewhat less reliability and increased variability in regions of moderate SERT density and poor reproducibility in low-density regions.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16644752

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  39 in total

1.  The 5-HT(2A) receptor and serotonin transporter in Asperger's disorder: A PET study with [¹¹C]MDL 100907 and [¹¹C]DASB.

Authors:  Ragy R Girgis; Mark Slifstein; Xiaoyan Xu; W Gordon Frankle; Evdokia Anagnostou; Stacey Wasserman; Lauren Pepa; Alexander Kolevzon; Anissa Abi-Dargham; Marc Laruelle; Eric Hollander
Journal:  Psychiatry Res       Date:  2011-11-12       Impact factor: 3.222

2.  Prediction of repeat-dose occupancy from single-dose data: characterisation of the relationship between plasma pharmacokinetics and brain target occupancy.

Authors:  Sergio Abanades; Jasper van der Aart; Julien A R Barletta; Carmine Marzano; Graham E Searle; Cristian A Salinas; Javaad J Ahmad; Richard R Reiley; Sabina Pampols-Maso; Stefano Zamuner; Vincent J Cunningham; Eugenii A Rabiner; Marc A Laruelle; Roger N Gunn
Journal:  J Cereb Blood Flow Metab       Date:  2010-10-13       Impact factor: 6.200

3.  Positron emission tomographic studies of brain dopamine and serotonin transporters in abstinent (+/-)3,4-methylenedioxymethamphetamine ("ecstasy") users: relationship to cognitive performance.

Authors:  Una D McCann; Zsolt Szabo; Melin Vranesic; Michael Palermo; William B Mathews; Hayden T Ravert; Robert F Dannals; George A Ricaurte
Journal:  Psychopharmacology (Berl)       Date:  2008-07-27       Impact factor: 4.530

4.  Simultaneous estimation of input functions: an empirical study.

Authors:  R Todd Ogden; Francesca Zanderigo; Stephen Choy; J John Mann; Ramin V Parsey
Journal:  J Cereb Blood Flow Metab       Date:  2009-12-09       Impact factor: 6.200

5.  Striatal and extrastriatal dopamine release measured with PET and [(18)F] fallypride.

Authors:  Mark Slifstein; Lawrence S Kegeles; Xiaoyan Xu; Judy L Thompson; Nina Urban; John Castrillon; Elizabeth Hackett; S-A Bae; Marc Laruelle; Anissa Abi-Dargham
Journal:  Synapse       Date:  2010-05       Impact factor: 2.562

6.  Optimization of preprocessing strategies in Positron Emission Tomography (PET) neuroimaging: A [11C]DASB PET study.

Authors:  Martin Nørgaard; Melanie Ganz; Claus Svarer; Vibe G Frokjaer; Douglas N Greve; Stephen C Strother; Gitte M Knudsen
Journal:  Neuroimage       Date:  2019-06-01       Impact factor: 6.556

7.  In vivo variation in same-day estimates of metabotropic glutamate receptor subtype 5 binding using [11C]ABP688 and [18F]FPEB.

Authors:  Christine DeLorenzo; Jean-Dominique Gallezot; John Gardus; Jie Yang; Beata Planeta; Nabeel Nabulsi; R Todd Ogden; David C Labaree; Yiyun H Huang; J John Mann; Fabrizio Gasparini; Xin Lin; Jonathan A Javitch; Ramin V Parsey; Richard E Carson; Irina Esterlis
Journal:  J Cereb Blood Flow Metab       Date:  2016-01-01       Impact factor: 6.200

8.  QModeling: a Multiplatform, Easy-to-Use and Open-Source Toolbox for PET Kinetic Analysis.

Authors:  Francisco J López-González; José Paredes-Pacheco; Karl Thurnhofer-Hemsi; Carlos Rossi; Manuel Enciso; Daniel Toro-Flores; Belén Murcia-Casas; Antonio L Gutiérrez-Cardo; Núria Roé-Vellvé
Journal:  Neuroinformatics       Date:  2019-01

9.  Serotonin transporter binding after recovery from bulimia nervosa.

Authors:  Rama Pichika; Monte S Buchsbaum; Ursula Bailer; Carl Hoh; Alex Decastro; Bradley R Buchsbaum; Walter Kaye
Journal:  Int J Eat Disord       Date:  2011-06-13       Impact factor: 4.861

10.  Cognitive impact of genetic variation of the serotonin transporter in primates is associated with differences in brain morphology rather than serotonin neurotransmission.

Authors:  H P Jedema; P J Gianaros; P J Greer; D D Kerr; S Liu; J D Higley; S J Suomi; A S Olsen; J N Porter; B J Lopresti; A R Hariri; C W Bradberry
Journal:  Mol Psychiatry       Date:  2009-09-01       Impact factor: 15.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.